According to this recent study, workplace screenings can complement routine skin cancer screenings. They inform participants about the existence and benefits of screenings and may have spillover effects for peers. They can also serve as another source of information on prevention and risk behaviours.
COMBI-i is a phase III trial evaluating spartalizumab, an anti–programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600–mutant unresectable or metastatic melanoma. The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by the results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.
Te Aho o Te Kahu, the Cancer Control Agency has once again begun to monitor the impact of COVID-19 on cancer diagnostic and treatment services. The fourth report looks at the number of cancer diagnoses and treatments to end of December 2021, compared to the same time period in the previous year/s to understand if the 2021 COVID-19 lockdown has impacted cancer diagnosis and treatment, and created or exacerbated inequities.
According to this recent study, the inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals.
According to this recent study, multiomic profiling showed advanced melanoma patients who did not respond to checkpoint inhibitor treatment had no common mechanisms of resistance.
This recent study evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). The study concludes that adjuvant dendritic cell vaccination with CD1c+ myeloid dendritic cells and/or plasmacytoid dendritic cells is feasible, safe and induced immunological responses in the majority of stage III melanoma patients.
This recent study assessed the efficacy of multispectral imaging (MSI) to predict Breslow thickness and developed a classification algorithm to determine optimal safety margins of the melanoma excision. The study concludes that this novel method may help predict the appropriate safety margins for curative melanoma excision.
According to this recent study, in determining the effectiveness of sun-safety programs, spectrophotometric evaluation of sun-induced skin pigmentation can allow for a more complete evaluation of self-reported sun exposure and sun-protective behavior.
This recent study evaluated whether an interactive educational activity using handheld dosimeters improved UV-related knowledge among Australian primary (elementary) school students. It concludes that the students had moderate knowledge about UV and sun protection, and knowledge improved significantly after a short interactive educational activity using handheld UV dosimeters.
The objectives of this recent study were to assess the reliability of an artificial intelligence (AI)-based clinical triage algorithm in classifying benign and malignant skin lesions and to evaluate the quality of images obtained in primary care using the study camera. Authors conclude that the AI algorithm demonstrates encouraging results, with high sensitivity and specificity, concordant with previous AI studies, and shows potential as a triage tool in conjunction with teledermatology to augment health care and improve access to dermatology.